Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neos names chief commercial officer

This article was originally published in Scrip

Executive Summary

Neos Therapeutics, a company developing a late-stage pipeline of innovative extended-release product candidates for the treatment of attention-deficit hyperactivity disorder, has appointed Thomas P McDonnell chief commercial officer – effective immediately. Prior to joining Neos, Mr McDonnell spent 10 years with Shire, most recently as vice-president of US marketing in the neuroscience business unit from December 2013 to March 2015. In this role, he led the US product strategy team responsible for the commercialization of Vyvanse and Intuniv into the ADHD market.

Related Companies

UsernamePublicRestriction

Register

SC028585

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel